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Pharmacogenetics research looks at variations in the human genome and ways in which 
genetic factors might influence individual’s response to drugs. We performed two 
pharmacogenetic studies on the immunosuppressive drugs, azathioprine and tacrolimus, 
to investigate the role of drug-metabolizing enzyme polymorphisms, alone or in 
combination with physiological factors, in avoiding severe drug reaction or in reducing 
pharmacokinetic (PK) variability. 
Azathioprine is a thiopurine drug, used mainly in acute lymphoblastic leukaemia, organ 
transplant and autoimmune disorders. The thiopurine methyltransferase (TPMT) 
enzyme is one of the major metabolizing enzymes of azathioprine and its activity level 
in human tissues is controlled by a common genetic polymorphism. Therefore, an 
azathioprine dose reduction is recommended to avoid severe adverse drug reactions in 
patients carrying mutations with a decreased TPMT activity. We investigated the TPMT 
genotype-phenotype relationship in a healthy unrelated population and a concordance 
rate of 71.6% between genotype and phenotype was observed. Interestingly, genetic 
factors seemed to be the major determinant of TPMT phenotype variability in adults, 
whereas wild type children showed a significantly higher TPMT activity compared to 
wild type adults, showing also significant differences according to the gender. 
Therefore, not only the genetic factors but also physiological features, such as age and 
gender, should be taken into consideration when assessing the TPMT phenotype.  
Tacrolimus is an immunosuppressive drug widely used in patients undergoing solid 
organ transplantation. This drug has a narrow therapeutic index, exposing patients to 
acute graft rejection and toxicity in cases of low or high blood concentrations, 
respectively. Therefore, it has been suggested to analyze some genetic factors, such as 
polymorphisms in genes coding for biotransformation enzymes like cytochrome P450 
isoenzyme 3A5 (CYP3A5), in order to reduce the great inter-individual PK variability 
after the initial tacrolimus dose. 
We investigated the influence of the CYP3A5 donor genotype in pediatric patients after 
liver transplantation correlating this with tacrolimus disposition on the first day of 
treatment. We confirmed that tacrolimus starting dose in pediatric liver transplant 
patients may be influenced by the liver donor’s CYP3A5 genotype but, again, also sex 
and age appeared to be associated with tacrolimus disposition. 
In conclusion, these studies emphasizes the fact that tailoring the azathioprine or 
tacrolimus dosage according to genetic and physiological factors in pediatric patients 
could improve the efficacy of these immunosuppressive therapies. 
 
